Back in December 2020, Congress appropriated $1.15 billion to the National Institutes of Health (NIH) specifically for Long COVID research. But that’s a drop in the bucket, given the challenges that lie ahead.
The goal of the research was to estimate the prevalence and cost of Long COVID. Here are some of the key findings:
22 million U.S. adults are living with Long Covid (LC) – close to 7 percent of the population.
7 million are experiencing Disabling Long Covid (DLC) – 2.3 percent of the population.
As of January 2022, the cumulative cost of LC is estimated at more than $386 billion. (This estimate includes lost wages, lost savings, and medical expenses incurred by individuals. It does not include costs incurred by businesses or government agencies.)
The macro economic costs of COVID have just begun.